Expansion of the Regenerative Medicine Market
First written in FY2024. 4 of 7 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-08-14.
0 other companies' latest entry also says "Worsened".
- 2026-08-14WorsenedEarnings
「一方、中国において細胞治療関連規制の強化が進められたことに伴い、一部細胞治療クリニックにおける診療活動が停滞し、細胞治療関連市場に影響がみられました。」
再生医療関連需要は堅調とする一方、中国の細胞治療関連規制強化により一部市場が停滞したことを記載している。 - FY2026AdvancedAnnual report
「Revenue was ¥2,539 million, up 11.9% year on year, and segment profit, or operating profit, was ¥946 million, up 23.7%. The tissue culture business served as the most stable earnings base within the Group and supported overall performance.」
The company reported growth in revenue and profit from the tissue culture business, supported by demand in the regenerative medicine and cell therapy fields and OEM orders. - 2026-05-15Cited as achievedRevision of earnings forecasts
「特に、OEM培地の受注が好調に推移し、主要取引先向け販売の拡大が売上成長を牽引しました。以上より、売上高は2,539百万円（前年同期比11.9％の増加）、セグメント利益（営業利益）は946百万円（前年同期比23.7％の増加）となり、組織培養事業は当社グループの中で最も安定した収益基盤として機能し、全社業績を下支えする結果となりました。」
再生医療関連需要を背景とする組織培養事業の成長について、OEM受注と売上増加を実績として引用している。 - FY2026-H1AdvancedAnnual report
「During the interim consolidated accounting period, demand for cell culture media in the tissue culture business remained firm, supported by increased research and development and clinical trial activity in regenerative medicine in Japan and overseas. In particular, the cell therapy market continued to expand across Asia, led by China, resulting in increased product sales in the region.」
The expansion of the regenerative medicine market continued in Japan and overseas, particularly across Asia led by China, and revenue from the tissue culture business increased 16.4% year on year. - FY2025AdvancedAnnual report
「Research and development and clinical trials in regenerative medicine are active both in Japan and overseas, and sales volume of the cell culture media used in these activities increased.」
Regarding the expansion of the regenerative medicine market, the company reported increased research and development and clinical trial activity in Japan and overseas, as well as higher culture media sales volume. Revenue from the tissue culture business increased 19.1% year on year. - FY2025-H1AdvancedAnnual report
「Research and development and clinical trials in regenerative medicine are expanding across Asia, particularly in China, and sales volume of the cell culture media used in these activities also increased.」
Regarding the expansion of the regenerative medicine market, the company reported growth in research and development, clinical trials and culture media sales volume in Asia, particularly China. - FY2024First statedAnnual report
「The regenerative medicine market was valued at ¥0.6 trillion in 2020 and is forecast to reach ¥11.6 trillion in 2040, indicating an expanding market.」
The company cited an external forecast showing the size of the regenerative medicine market.